Patient Characteristics | Pazopanib-induced non-HTN CV toxicity (NÂ =Â 12) | No Pazopanib-induced non-HTN CV toxicity (NÂ =Â 23) | P Value |
---|---|---|---|
Male Gender | 5 (42) | 15 (65) | 0.282 |
Age, years | 66 [61-71] | 57 [52-65] | 0.006 |
LVEF, % | *60 [59-67] | **62.5 [59-66] | 0.712 |
Systolic BP, mm Hg | 124.1 [120.8-130.8] | 127.7 [122-132.6] | 0.728 |
Diastolic BP, mm Hg | 70.0 [65.9-73.5] | 72 [67.9-79.3] | 0.297 |
Heart Failure | 0 (0) | 2 (9) | 0.536 |
LV Dysfunction | 4 (33) | 3 (13) | 0.200 |
Diabetes Mellitus | 5 (42) | 10 (43) | 1 |
Hypertension | 7 (58) | 14 (61) | 1 |
Dyslipidemia | 8 (67) | 9 (39) | 0.164 |
GFRÂ <Â 60Â mL/min/1.73Â m2 | 9 (75) | 11 (48) | 0.163 |
CAD/PAD | 3 (25) | 2 (9) | 0.313 |
CVA/TIA | 3 (25) | 0 (0) | 0.034 |
Dysrhythmia | 3 (25) | 4 (17) | 0.670 |
Thromboembolism | 1 (8) | 6 (26) | 0.380 |
Smoker*, n (%) | 7 (58) | 13 (57) | 1 |
BMI (kg/m2) | 27.6 [23.6-31.8] | 28.5 [21.9-32.9] | 0.627 |
ACEIs or ARBs | 6 (50) | 8 (35) | 0.383 |
Beta Blockers | 4 (33) | 8 (35) | 1 |
Statin | 6 (50) | 7 (30) | 0.256 |
Pazopanib dose reduction | 3 (25) | 3 (13) | 0.391 |
Follow-up time, months | 11.7 [4.2-20.9] | 6.9 [2.1-17.7] | 0.509 |